Marshall Wace
VERV

Marshall Wace’s Verve Therapeutics VERV Stock Holding History

Marshall Wace’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,681
Closed -$355K – 3211
2025
Q1 		$355K Buy
+77,681
New +$520K ﹤0.01% 2201
2023
Q3 		– Sell
-51,235
Closed -$961K – 2724
2023
Q2 		$961K Buy
+51,235
New +$853K ﹤0.01% 1731
2022
Q3 		– Sell
-50,499
Closed -$772K – 3823
2022
Q2 		$772K Buy
+50,499
New +$782K ﹤0.01% 2586
2022
Q1 		– Sell
-939
Closed -$35K – 4059
2021
Q4 		$35K Buy
+939
New +$39.4K ﹤0.01% 3633

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace's VERV Position: Q2 2025 in Review

Marshall Wace sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 77,681 shares — an estimated $355K sold.

Marshall Wace first reported a position in VERV in Q4 2021 and held it in 4 quarters. The position peaked at $961K in Q2 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Marshall Wace reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 77,681 Verve Therapeutics shares in Q2 2025, an estimated $355K.
  • Marshall Wace first reported a position in Verve Therapeutics in Q4 2021 and held it in 4 quarters.
  • Marshall Wace's Verve Therapeutics position peaked at $961K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.